论文部分内容阅读
目的探讨酒石酸美托洛尔辅助治疗慢性充血性心力衰竭(CHF)的有效性和安全性。方法将80例慢性充血性心力衰竭的患者随机分为实验组和对照组,每组各40例,对照组的患者给予常规治疗,实验组在常规治疗的基础上加用酒石酸美托洛尔治疗。结果实验组的总有效率和显效率都明显高于对照组,两组间的疗效有显著性差异(P<0.05)。结论在常规治疗的基础上加用酒石酸美托洛尔治疗CHF的效果显著,并且不良反应轻微,适合运用于临床的治疗。
Objective To investigate the efficacy and safety of metoprolol tartrate adjuvant in the treatment of chronic congestive heart failure (CHF). Methods Eighty patients with chronic congestive heart failure were randomly divided into experimental group and control group, 40 cases in each group. Patients in control group were given routine treatment. Experimental group was treated with Metoprolol tartrate . Results The total effective rate and markedly effective rate in the experimental group were significantly higher than those in the control group, with significant differences between the two groups (P <0.05). Conclusion The addition of metoprolol tartrate plus CHF on the basis of conventional treatment has significant effect and mild adverse reactions, so it is suitable for clinical treatment.